GlassScriptPhysician profile
Tracy Martinez
NPI 1528568441
$1,923.97
in general payments reported to CMS, 2019-2025
26 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $704 · 2022: $281 · 2023: $365 · 2024: $264 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.88 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $280.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $270.67 | 2021-2025 | Injectafer |
| Organon LLC | $176.90 | 2022 | |
| Lilly USA, LLC | $121.22 | 2021-2025 | Jardiance, Mounjaro |
| Exact Sciences Corporation | $73.10 | 2023-2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $61.40 | 2024-2025 | |
| Pacira Therapeutics, INC. | $58.03 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $57.59 | 2022-2025 | Seglentis, Livalo, Zoryve |
| Amarin Pharma, INC. | $44.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.56 | 2023 | Xifaxan |
| Pfizer INC. | $39.75 | 2021-2023 | |
| Glaxosmithkline, LLC. | $29.36 | 2023 | Shingrix, Arexvy |
| Pacira Pharmaceuticals Incorporated | $28.41 | 2023-2024 | Iovera, Exparel, Zilretta |
| Biohaven Pharmaceutical Holding Company LTD. | $27.13 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.23 | 2023 | |
| Eisai INC. | $21.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2023 | Jardiance, Synjardy |
| Biohaven Pharmaceuticals, INC. | $20.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.25 | 2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $20.12 | 2022 | |
| Esperion Therapeutics, INC. | $18.87 | 2022 | |
| Inspire Medical Systems, INC. | $16.36 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $15.08 | 2021 | |
| Merck Sharp & Dohme LLC | $13.43 | 2021 | |
| Genentech USA, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.